Clinical Trials, Research and Development
March 6, 2023
Via: Biopharma DiveBased on the latest data, BridgeBio has started enrolling children in a Phase 3 trial of infigratinib in achondroplasia and also plans to develop the medicine for patients with a closely related skeletal abnormality known as hypochondroplasia. The company has […]